Home » Stocks » Zealand Pharma A/S

Zealand Pharma A/S (ZEAL)

Stock Price: $40.37 USD 0.23 (0.57%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Pre-market: $40.05 -0.32 (-0.79%) Oct 20, 7:16 AM

Stock Price Chart

Key Info

Market Cap 1.60B
Revenue (ttm) 5.82M
Net Income (ttm) 581.28M
Shares Out 39.71M
EPS (ttm) 3.00
PE Ratio 13.46
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $40.37
Previous Close $40.14
Change ($) 0.23
Change (%) 0.57%
Day's Open 41.16
Day's Range 40.37 - 41.16
Day's Volume 762
52-Week Range 22.00 - 44.60

More Stats

Market Cap 1.60B
Enterprise Value 1.43B
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 39.71M
Float n/a
EPS (basic) n/a
EPS (diluted) 3.00
FCF / Share 3.20
Dividend n/a
Dividend Yield n/a
Earnings Yield 7.43%
FCF Yield 6.13%
Payout Ratio n/a
Shares Short 218,952
Short Ratio 32.96
Short % of Float n/a
Beta 1.05
PE Ratio 13.46
Forward PE n/a
P/FCF Ratio 16.31
PS Ratio 275.26
PB Ratio 5.78
Revenue 5.82M
Operating Income 100.06M
Net Income 581.28M
Free Cash Flow 98.32M
Net Cash 177.80M
Net Cash / Share 4.48
Gross Margin 100.00%
Operating Margin 1,717.86%
Profit Margin 1,530.60%
FCF Margin 1,687.95%
ROA -19.27%
ROE -39.36%
ROIC 294.20%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$44.78*
(10.92% upside)
Low
36.6
Current: $40.37
High
48.4
Target: 44.78
*Average 12-month USD price target from 8 stock analysts.

Financial Performance

Financial numbers in millions DKK.

Financial Overview

Year2018201720162015
Revenue37.98136231183
Revenue Growth-72.14%-40.95%26.45%-
Gross Profit37.98136231183
Operating Income652-249-119-85.74
Net Income581-275-157-118
Shares Outstanding30.7530.0930.09-
Earnings Per Share18.94-9.88-6.47-5.13
Operating Cash Flow-460-27940.90-225
Capital Expenditures1,101-7.11-2.60-4.04
Free Cash Flow641-28638.30-229
Cash & Equivalents1,159664323419
Total Debt-136332313
Net Cash / Debt1,159528-8.91106
Assets1,230721683628
Liabilities114207416383
Book Value1,116515267245
Numbers in millions DKK, except per-share numbers.

Company Profile

Company Details

Full Name Zealand Pharma A/S
Country Denmark
Employees 313
CEO Emmanuel Dulac

Stock Information

Ticker Symbol ZEAL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ZEAL
IPO Date August 9, 2017

Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.